These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 36164749)

  • 1. Prognosis and Treatment of Metastatic Breast Cancer From A Real-World Scenario in China: A Retrospective Cohort Study.
    Xie Y; Ma J; Xia X; Zheng H; Gou Q
    Cancer Control; 2022; 29():10732748221130568. PubMed ID: 36164749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Possible clinical cure of metastatic breast cancer: lessons from our 30-year experience with oligometastatic breast cancer patients and literature review.
    Kobayashi T; Ichiba T; Sakuyama T; Arakawa Y; Nagasaki E; Aiba K; Nogi H; Kawase K; Takeyama H; Toriumi Y; Uchida K; Kobayashi M; Kanehira C; Suzuki M; Ando N; Natori K; Kuraishi Y
    Breast Cancer; 2012 Jul; 19(3):218-37. PubMed ID: 22532161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinicopathological characteristics and prognosis of different molecular types of breast cancer].
    Liu ZF; Chen C; Yao XL; Sun SR
    Zhonghua Yi Xue Za Zhi; 2016 Jun; 96(22):1733-7. PubMed ID: 27356638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-line treatment patterns and clinical outcomes in patients with HER2-positive and hormone receptor-positive metastatic breast cancer from registHER.
    Tripathy D; Kaufman PA; Brufsky AM; Mayer M; Yood MU; Yoo B; Quah C; Yardley D; Rugo HS
    Oncologist; 2013; 18(5):501-10. PubMed ID: 23652380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Capecitabine after anthracycline and taxane exposure in HER2-negative metastatic breast cancer patients: response, survival and prognostic factors.
    Gilabert M; Bertucci F; Esterni B; Madroszyk A; Tarpin C; Jacquemier J; Extra JM; Viens P; Gonçalves A
    Anticancer Res; 2011 Mar; 31(3):1079-86. PubMed ID: 21498742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of the efficacy of successive endocrine therapies in hormone receptor-positive and HER2-negative metastatic breast cancer: a real-life multicentre national study.
    Le Saux O; Lardy-Cleaud A; Frank S; Debled M; Cottu PH; Pistilli B; Vanlemmens L; Leheurteur M; Lévy C; Laborde L; Uwer L; D'hondt V; Berchery D; Lorgis V; Ferrero JM; Perrocheau G; Courtinard C; Mouret-Reynier MA; Velten M; Breton M; Parent D; Chabaud S; Robain M; Bachelot T
    Eur J Cancer; 2019 Sep; 118():131-141. PubMed ID: 31330488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008-2016.
    Deluche E; Antoine A; Bachelot T; Lardy-Cleaud A; Dieras V; Brain E; Debled M; Jacot W; Mouret-Reynier MA; Goncalves A; Dalenc F; Patsouris A; Ferrero JM; Levy C; Lorgis V; Vanlemmens L; Lefeuvre-Plesse C; Mathoulin-Pelissier S; Petit T; Uwer L; Jouannaud C; Leheurteur M; Lacroix-Triki M; Courtinard C; Perol D; Robain M; Delaloge S
    Eur J Cancer; 2020 Apr; 129():60-70. PubMed ID: 32135312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Analysis of risk factors of axillary lymph node metastasis and prognosis in T1 breast cancer: a large-scale retrospective study based on the SEER database].
    Wang WY; Meng XZ; Li N; Zeng HM; Liu JX; Feng KX; Wang PL; Wang X
    Zhonghua Yi Xue Za Zhi; 2021 Jul; 101(27):2152-2158. PubMed ID: 34275251
    [No Abstract]   [Full Text] [Related]  

  • 9. Real world initial palliative treatment patterns and clinical outcomes in premenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer: A study of the National Cancer Center, China.
    Li Y; Mo H; Guan X; Lin S; Wang Z; Chen Y; Chen S; Li Q; Cai R; Wang J; Luo Y; Fan Y; Yuan P; Zhang P; Li Q; Ma F; Xu B
    Breast; 2022 Feb; 61():129-135. PubMed ID: 34995922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of clinicopathological characteristics and prognostic factors in 54 metaplastic breast carcinoma patients from northwest China.
    Du J; Wu S; Liu J; Guo B; Li J; Li W; Zhang Y; Song H; Shu W; Li Z; Zhu X
    Cytojournal; 2024; 21():31. PubMed ID: 39411170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment outcome and prognostic factors for patients with bone-only metastases of breast cancer: a single-institution retrospective analysis.
    Niikura N; Liu J; Hayashi N; Palla SL; Tokuda Y; Hortobagyi GN; Ueno NT; Theriault RL
    Oncologist; 2011; 16(2):155-64. PubMed ID: 21266401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib.
    Prat A; Cheang MC; Galván P; Nuciforo P; Paré L; Adamo B; Muñoz M; Viladot M; Press MF; Gagnon R; Ellis C; Johnston S
    JAMA Oncol; 2016 Oct; 2(10):1287-1294. PubMed ID: 27281556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival and prognostic factors in oligometastatic breast cancer.
    van Ommen-Nijhof A; Steenbruggen TG; Capel L; Vergouwen M; Vrancken Peeters MT; Wiersma TG; Sonke GS
    Breast; 2023 Feb; 67():14-20. PubMed ID: 36549169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of hormone receptor status on the durable response of trastuzumab-based therapy in metastatic breast cancer.
    Park HS; Sohn J; Kim SI; Park S; Park HS; Gho SG; Chung HC; Paik S; Kim GM
    Breast Cancer Res Treat; 2017 Jun; 163(2):255-262. PubMed ID: 28243895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploring prognostic factors for HER2-positive metastatic breast cancer: a retrospective cohort study in a major Swiss hospital.
    Bringolf L; Pestalozzi B; Fink D; Dedes K
    Swiss Med Wkly; 2016; 146():w14393. PubMed ID: 28102883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinicopathological features and prognostic factors of breast cancer patients with inguinal lymph node metastases: a report of 17 cases].
    Li Q; Xu BH; Zhang P; Li Q; Yuan P; Wang JY; Luo Y; Ma F; Fan Y; Li Q
    Zhonghua Zhong Liu Za Zhi; 2013 Mar; 35(3):207-11. PubMed ID: 23880002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term outcomes of oligometastatic breast cancer patients treated with curative intent: an updated report.
    Nagasaki E; Kudo R; Tamura M; Hayashi K; Uwagawa T; Kijima Y; Nogi H; Takeyama H; Suzuki M; Nishikawa M; Yano S; Kobayashi T
    Breast Cancer; 2021 Sep; 28(5):1051-1061. PubMed ID: 33840010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical features and prognostic factors for extracranial oligometastatic breast cancer in China.
    Lan B; Abudureheiyimu N; Zhang J; Wang C; Jiang S; Wang J; Ma F; Luo Y; Chen S; Xu B; Fan Y
    Int J Cancer; 2020 Dec; 147(11):3199-3205. PubMed ID: 32535918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In real life, one-quarter of patients with hormone receptor-positive metastatic breast cancer receive chemotherapy as initial palliative therapy: a study of the Southeast Netherlands Breast Cancer Consortium.
    Lobbezoo DJ; van Kampen RJ; Voogd AC; Dercksen MW; van den Berkmortel F; Smilde TJ; van de Wouw AJ; Peters FP; van Riel JM; Peters NA; de Boer M; Peer PG; Tjan-Heijnen VC
    Ann Oncol; 2016 Feb; 27(2):256-62. PubMed ID: 26578730
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic Value of Modified IHC4 Score in Patients with Estrogen Receptor-Positive Metastatic Breast Cancer.
    Jin L; Chen K; Tan C; Li J; Luo J; Yang Y; Li Y; Li S; Zhu L; Hu Y; Liu F; You Q; Peng M; Jiang Z; Liu Q
    Oncologist; 2020 Aug; 25(8):e1170-e1180. PubMed ID: 32476192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.